Clinical Trial Results: A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of AXS-05 in agitation associated with Alzheimer’s disease and related dementias; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation in Dementia
• Alzheimer Disease

Drugs mentioned

• AXS-05 (dextromethorphan-quinidine)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-08-13